Brennan Winkler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brennan Winkler has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Joshua H. Lipschutz
Medical University of South Carolina
2 shared publications Kasey Lerner
Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States
2 shared publicationsXiaofeng Zuo
Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States
2 shared publicationsYanhui Su
Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States
2 shared publicationsYujing Dang
Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States
2 shared publications- Ahmed Ibrahim Kamal
Internal Medicine Department, Nephrology Division, Medical University of South Carolina
1 shared publication
Latest Publications
- 1 July 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (1) , F61-F76
Cilia-deficient renal tubule cells are primed for injury with mitochondrial defects and aberrant tryptophan metabolism
Mitochondria are centrally involved in acute kidney injury (AKI). Here, we show that cilia-deficient renal tubule cells both in vitro in cell culture and in vivo in mice are primed for injury with mitochondrial defects and aberrant tryptophan metabolism. These data suggest therapeutic strategies such as enhancing ciliogenesis or improving mitochondrial function to protect patients at risk for AKI.
- 1 July 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 327 (1) , F61-F76
Cilia-deficient renal tubule cells are primed for injury with mitochondrial defects and aberrant tryptophan metabolism
Mitochondria are centrally involved in acute kidney injury (AKI). Here, we show that cilia-deficient renal tubule cells both in vitro in cell culture and in vivo in mice are primed for injury with mitochondrial defects and aberrant tryptophan metabolism. These data suggest therapeutic strategies such as enhancing ciliogenesis or improving mitochondrial function to protect patients at risk for AKI.
- 1 January 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 326 (1) , F20-F29
β2-Adrenergic receptor agonists as a treatment for diabetic kidney disease
Diabetic nephropathy is the most common cause of ESKD. Formoterol, a long-acting β2-adrenergic receptor (β2-AR) agonist, reversed diabetic nephropathy in murine models of type 1 and 2 diabetes. In humans, there was an association with protection from progression of CKD in patients with COPD, by means of β2-AR agonist intake, compared with those without COPD. These data indicate that β2-AR agonists, especially formoterol, could be a new treatment for diabetic nephropathy and other forms of CKD.
- 1 January 2024
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 326 (1) , F20-F29
β2-Adrenergic receptor agonists as a treatment for diabetic kidney disease
Diabetic nephropathy is the most common cause of ESKD. Formoterol, a long-acting β2-adrenergic receptor (β2-AR) agonist, reversed diabetic nephropathy in murine models of type 1 and 2 diabetes. In humans, there was an association with protection from progression of CKD in patients with COPD, by means of β2-AR agonist intake, compared with those without COPD. These data indicate that β2-AR agonists, especially formoterol, could be a new treatment for diabetic nephropathy and other forms of CKD.